Bausch + Lomb Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Bausch + Lomb de 63.2% y 6.8% por año respectivamente. Se prevé que el BPA crezca en un 61.8% al año. Se espera que la rentabilidad financiera sea de 7.7% en 3 años.

Información clave

65.7%

Tasa de crecimiento de los beneficios

66.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.1%
Tasa de crecimiento de los ingresos	6.2%
Rentabilidad financiera futura	5.4%
Cobertura de analistas	Good
Última actualización	06 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate

Apr 30

Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price

Jan 14

Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)

Nov 08

Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S

Nov 03

An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued

Aug 15

Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease

Aug 09

These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong

May 09

Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate

Mar 28

Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M

Feb 22

Bausch + Lomb's photodynamic laser gets FDA approval for use with Visudyne

Feb 01

Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect

Jan 24

Bausch + Lomb acquires AcuFocus for cataract lens

Jan 17

Bausch + Lomb says Joseph Papa to serve as CEO until at least March next year

Dec 22

Bausch + Lomb stock rises on FDA nod for contact lens rehydrating drops

Dec 13

Bausch + Lomb: A Solid Play In Challenging Economic Times

Nov 09

Bausch + Lomb reports Q3 mixed earnings; narrows FY22 guidance range

Nov 02

Bausch Health retains advisors following patent loss

Aug 22

Previsiones de crecimiento de beneficios e ingresos

NYSE:BLCO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	5,199	129	776	N/A	8
12/31/2025	4,944	-62	512	N/A	12
12/31/2024	4,658	-236	310	N/A	13
3/31/2024	4,314	-337	N/A	N/A	N/A
12/31/2023	4,146	-260	-198	-17	N/A
9/30/2023	3,969	-207	-20	127	N/A
6/30/2023	3,904	-141	-60	106	N/A
3/31/2023	3,810	-104	116	286	N/A
12/31/2022	3,768	6	170	345	N/A
9/30/2022	3,773	58	144	348	N/A
6/30/2022	3,780	136	398	594	N/A
3/31/2022	3,773	175	482	688	N/A
12/31/2021	3,765	182	680	873	N/A
9/30/2021	3,708	-78	636	845	N/A
6/30/2021	3,675	-53	539	776	N/A
3/31/2021	3,517	-44	370	618	N/A
12/31/2020	3,412	-18	263	522	N/A
12/31/2019	3,778	298	619	799	N/A
12/31/2018	3,665	710	662	763	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BLCO sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que BLCO sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que BLCO sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (6.8% al año) de BLCO crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6.8% al año) de BLCO crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de BLCO sea baja dentro de 3 años (7.7%).

Bausch + Lomb Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 147%, revenue upgraded

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2024

Bausch + Lomb Corporation Raises Revenue Guidance for the Full Year of 2023

Consensus EPS estimates upgraded to US$0.58 loss

Consensus EPS estimates fall by 235%, revenue upgraded

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2023

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate

Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

Bausch + Lomb Corporation to Report Q1, 2024 Results on May 01, 2024

Bausch + Lomb Corporation, Annual General Meeting, May 29, 2024

Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?

High number of new directors

Bausch + Lomb Corporation Announces Board Changes

Consensus EPS estimates fall by 147%, revenue upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2024

Many Still Looking Away From Bausch + Lomb Corporation (NYSE:BLCO)

Bausch + Lomb Corporation to Report Q4, 2023 Results on Feb 21, 2024

Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound

Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price

Bausch + Lomb Corporation Receives FDA Approval for TENEO Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)

New major risk - Financial position

Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Raises Revenue Guidance for the Full Year of 2023

Bausch + Lomb Will Present New Scientific Data and Analyses At American Academy of Ophthalmology Annual Meeting

Consensus EPS estimates upgraded to US$0.58 loss

Bausch + Lomb Corporation to Report Q3, 2023 Results on Nov 01, 2023

Consensus EPS estimates fall by 235%, revenue upgraded

Bausch + Lomb Corporation Launches LUMIFY EYE ILLUMINATIONS in the United States

Bausch + Lomb Corporation Launches MIEBO (Perfluorohexyloctane Ophthalmic Solution) in the United States

An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued

Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Announces Executive Changes

Now 21% undervalued

Bausch + Lomb Corporation to Report Q2, 2023 Results on Aug 02, 2023

Bausch + Lomb Corporation (NYSE:BLCO) agreed to acquire Blink® product line of eye and contact lens drops of Johnson & Johnson Vision for approximately $110 million.

Bausch + Lomb Corporation (NYSE:BLCO) signed an agreement to acquire ophthalmology assets from Novartis AG (SWX:NOVN) for $2.5 billion.

Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United States

Bausch + Lomb Corporation to Present the Results of 11 Scientific Poster Presentations Inviding the Company's Consumer, Vision Care and Pharmaceutical Products

Bausch + Lomb Corporation Launches Biotrue Hydration Boost Contact Lens Rehydrating Drops in the United States

Bausch + Lomb Corporation Launches Bausch + Lomb Infuse®? Multifocal Silicone Hydrogel Contact Lenses in the United States

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation and Novaliq Announce Fda Approval of Miebo™? (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2023

Consensus EPS estimates fall by 30%

Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 45%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M

Now 21% undervalued

Bausch + Lomb Corporation Announces Board Appointments, Effective March 6, 2023

Bausch + Lomb and Modulight Announces FDA Approval of ML6710i Photodynamic Laser

Bausch + Lomb's photodynamic laser gets FDA approval for use with Visudyne

Bausch + Lomb Corporation, Annual General Meeting, Apr 24, 2023

Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect

Bausch + Lomb Corporation to Report Q4, 2022 Results on Feb 22, 2023

Bausch + Lomb Corporation (NYSE:BLCO) acquired AcuFocus, Inc.

Bausch + Lomb acquires AcuFocus for cataract lens

Bausch + Lomb Corporation Announces the U.S. Introduction of Preservision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Bausch + Lomb Corporation Enters into CEO Separation Agreement with Joseph C. Papa

Bausch + Lomb says Joseph Papa to serve as CEO until at least March next year

Bausch + Lomb Corporation Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops

Bausch + Lomb stock rises on FDA nod for contact lens rehydrating drops

Bausch + Lomb: A Solid Play In Challenging Economic Times

Third quarter 2022 earnings: EPS misses analyst expectations

Bausch + Lomb Corporation Revises Revenue Guidance for the Year 2022